Clinical ResearchHeart FailureEffects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction: Results From PROTECT (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function)
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned subsidiary of Merck & Co, Inc. Dr. Voors has received speakers' fees from and served as a consultant to Merck. Dr. Dittrich has ownership in NovaCardia, and has served as a consultant to and is a minor shareholder in Merck. Dr. Massie has received speaking honorarium from CME providers for satellite symposia supported by Merck-NovaCardia, and has received compensation from Averion for his role as Co-Principal Investigator of the PROTECT trial. Drs. DeLucca and Mansoor are employees of Merck. Dr. Metra has received honoraria and travel reimbursement from NovaCardia, Merck, Corthera, Novartis, Cardiokine, and Servier. Dr. Ponikowski has received honoraria from Merck, NovaCardia, and Corthera. Drs. Cotter and Weatherley are employees of Momentum Research. Drs. Teerlink, Cleland, and Givertz have received research grants from NovaCardia and served as consultants to Merck. Gregg Fonarow, MD, served as Guest Editor for this paper. Please note: Based upon the results of the Phase III PROTECT trial assessing the effects of rolofylline on short- and long-term outcomes presented at the European Society of Cardiology in 2009, Merck and Co., Inc. determined that the lack of efficacy did not support further development of this compound for the treatment of patients with acute decompensated HF.